
## Maria F Paton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1685366/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects of Vitamin D on Cardiac Function inÂPatients With Chronic HF. Journal of the American College of Cardiology, 2016, 67, 2593-2603.	2.8	179
2	Predicting oneâ€year mortality in heart failure using the â€~Surprise Question': a prospective pilot study. European Journal of Heart Failure, 2019, 21, 227-234.	7.1	40
3	Infection-Related Hospitalization in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006746.	3.9	39
4	Chronotropic Incompetence DoesÂNotÂLimit Exercise Capacity inÂChronicÂHeartÂFailure. Journal of the American College of Cardiology, 2016, 67, 1885-1896.	2.8	32
5	Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes. Diabetes Care, 2018, 41, 136-142.	8.6	32
6	Vitamin D deficiency is an independent predictor of mortality in patients with chronic heart failure. European Journal of Nutrition, 2019, 58, 2535-2543.	3.9	23
7	Association of heart failure and its comorbidities with loss of life expectancy. Heart, 2021, 107, 1417-1421.	2.9	21
8	Chronic heart failure with diabetes mellitus is characterized by a severe skeletal muscle pathology. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 394-404.	7.3	20
9	Divergent skeletal muscle mitochondrial phenotype between male and female patients with chronic heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 79-88.	7.3	15
10	Rate-Response Programming Tailored toÂthe Force-Frequency Relationship Improves Exercise Tolerance in ChronicÂHeart Failure. JACC: Heart Failure, 2018, 6, 105-113.	4.1	14
11	To the Editor—New phones, old problem? Interference with cardiovascular implantable electronic devices by phones containing magnets. Heart Rhythm, 2021, 18, 1041.	0.7	13
12	Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure. Circulation, 2020, 141, 1693-1703.	1.6	12
13	Prognostic Significance of Incidental Nonsustained Ventricular Tachycardia Detected on Pacemaker Interrogation. American Journal of Cardiology, 2019, 123, 409-413.	1.6	8
14	Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure. Journal of Cardiovascular Medicine, 2021, 22, 848-856.	1.5	6
15	Feasibility and validation of trans-valvular flow derived by four-dimensional flow cardiovascular magnetic resonance imaging in pacemaker recipients. Magnetic Resonance Imaging, 2020, 74, 46-55.	1.8	5
16	Projected longevities of cardiac implantable defibrillators: a retrospective analysis over the period 2007–17 and the impact of technological factors in determining longevity. Europace, 2020, 22, 149-155.	1.7	4
17	Prospective evaluation and long-term follow-up of patients referred to secondary care based upon natriuretic peptide levels in primary care. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 218-224.	4.0	3
18	Impact of COVID-19 on UK stress echocardiography practice: insights from the EVAREST sites. Echo Research and Practice, 2021, 8, 1-8.	2.5	3

Maria F Paton

#	Article	IF	CITATIONS
19	Detrimental Immediate- and Medium-Term Clinical Effects of Right Ventricular Pacing in Patients With Myocardial Fibrosis. Circulation: Cardiovascular Imaging, 2021, 14, e012256.	2.6	3
20	Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial. BMJ Open, 2019, 9, e028613.	1.9	2
21	Pacemaker longevity: understanding what drains the battery. British Journal of Cardiac Nursing, 2019, 14, 1-9.	0.1	1
22	Heart failure and right ventricular pacing – how to avoid the need for cardiac resynchronization therapy. Expert Review of Medical Devices, 2019, 16, 35-43.	2.8	1
23	Diabetes, gender and deterioration in estimated glomerular filtration rate in patients with chronic heart failure: Ten-year prospective cohort study. Diabetes and Vascular Disease Research, 2021, 18, 147916412098443.	2.0	1
24	Diabetes mellitus and the causes of hospitalisation in people with heart failure. Diabetes and Vascular Disease Research, 2022, 19, 147916412110739.	2.0	1
25	Advances in cardiac resynchronization and implantable cardioverter/defibrillator therapy: Medtronic Cobalt and Crome. Future Cardiology, 2021, 17, 609-618.	1.2	Ο
26	Response by Gierula et al to Letter Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study― Circulation, 2020, 142, e319-e320.	1.6	0
27	Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial. PLoS ONE, 2021, 16, e0259450.	2.5	Ο